Evaluation of Long Term Safety and Efficacy of Glepaglutide in Treatment of SBS

PHASE3Active, not recruitingINTERVENTIONAL
Enrollment

145

Participants

Timeline

Start Date

May 7, 2019

Primary Completion Date

October 31, 2026

Study Completion Date

October 31, 2026

Conditions
Short Bowel Syndrome
Interventions
DRUG

glepaglutide

Glucagon-Like Peptide-2 (GLP-2) analog

Trial Locations (27)

10029

Mount Sinai Hospital, New York

20007

Georgetown University Medical Center, Washington D.C.

44195

Cleveland Clinic, Cleveland

53127

Universitätsklinikum Bonn, Bonn

55905

Mayo Clinic College of Medicine, Rochester

60637

University of Chicago Children's Hospital, Chicago

68198-3285

University of Nebraska Medical Center, Omaha

Vanderbilt University Medical Center, Nashville, Nashville

Unknown

UZ Leuven, Leuven

The Royal Alexandra Hospital, Edmonton

University Health Network - Toronto General Hospital, Toronto

Rigshospitalet, Copenhagen

Hôpital Beaujon, Clichy

Centre Hospitalier Lyon-Sud, Pierre-Bénite

Charité - Universitätsmedizin Berlin, Berlin

Universitätsklinikum Frankfurt - Med. Klinik I, Frankfurt

Asklepios Kliniken Hamburg GmbH, Hamburg

Universitätsmedizin Rostock, Rostock

UMC Radboud Nijmegen, Nijmegen

Wojewodzki Specjalistyczny Szpital im. M. Pirogowa w Lodzi, Lodz

Solumed, Poznan

Szpital Skawina sp. z o.o. im. Stanley Dudricka, Skawina

St Mark's Hospital, Harrow

UCLH Foundation NHS Trust, London

University of East Anglia, Norwich

University Hospital Southampton NHS Foundation Trust, Southampton

N6A 4V2

Western University, London

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Zealand Pharma

INDUSTRY